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Making predictions is difficult, especially concerning the future. 
Historia magistra vitae. 
 
Introduction 
 
 Less than a decade ago, one would begin such a paper stating that non-Hodgkin's 
lymphomas (NHL) are treated with chemotherapy, radiation and steroids and that 
improvements should be sought by improving cytotoxic treatment schedules and using high-
dose therapy and auto- or alografting in an appropriate manner. However, the last few years 
have witnessed a revolution in the treatment of non-Hodgkin's lymphomas (NHL) that 
resulted from the use of a different class of drugs, namely monoclonal antibodies. In the 
meantime, smart drugs, proteasome inhibitors, immunomodulators, histone deacetylase 
(HDAC) inhibitors and antiangiogenic drugs are being tested and in some instances approved 
for the treatment of other types of cancers. On the other hand, improvements in understanding 
lymphoma biology have enabled us to realize that all NHLs are not created equal and that 
different prognostic groups can be identified even within single histological subtypes. All 
these new drugs and concepts have created a shifty field with a lot of possibilities making 
predictions of future treatment approaches very difficult. 
 
Monoclonal antibodies 
 
The introduction of rituximab, a humanized murine monoclonal antibody directed 
against the CD20 antigen, has led to an improvement of outcomes of patients with B-cell 
NHL unparalleled since the invention of CHOP chemotherapy more than 30 years ago (1). 
The addition of rituximab to standard chemotherapy has improved all outcomes studied, 
including overall survival, in practically every phase III trial performed, be it first-line or 
salvage treatment, indolent or aggressive NHL etc. All this has been achieved without 
increasing treatment-related toxicity, making this success even more fascinating. Indeed, 
rituximab seems to be a lucky jack-pot winner and in retrospective it is hard to imagine a 
better designed monoclonal antibody. The CD20 antigen is present in all developmental 
stages of B-cells from late lymphoblasts to preplasmocytes. Therefore, rituximab is active 
against all B-NHL types but spares hematopoietic progenitors and immunoglobulin-secreting 
cells, thus resulting in low toxicity. CD20 antigen is not internalized nor shed, thus an 
antibody binding to it will remain on the cell surface for a prolonged period of time. Also, 
there will be no loss of antibodies due to binding to soluble parts of the antigen. The Fc 
portion of the antibody activates type 1 immunologic reactions. Presumably, these 
immunologic reactions are important for the activity of the drug but, surprisingly, this has not 
been proven yet (2). 
 The success of rituximab has led to a flood of me-too antibodies, either directed 
against different antigens or against CD20 but with some presumed improvement. However, 
their success is by no means guaranteed. One should keep in mind that rituximab was not the 
first antibody used for treatment of lymphomas. This title belongs to alemtuzumab, directed 
against CD52 (1,3). After a cautious start, alemtuzumab was almost abandoned because of 
toxicity, until improvements in infection prophylaxis and a more ambitious industrial sponsor 
made it resurface in the treatment of CLL. CD52 is present also on T-cells and treatment with 
alemtuzumab results in T-cell depletion, mimicking AIDS. It is therefore not surprising that 
lessons from the AIDS epidemic have taught us infection prophylaxis methods necessary for 
safe administration of alemtuzumab. While the drug is registered for treatment of fludarabin-
refractory CLL, unfortunately after more than a decade no randomized trials have been 
performed to prove its efficacy in T-cell NHL.  
Radioimmunotherapeutic agents are monoclonal antibodies conjugated with 
radioactive isotopes (4). Their antitumor activity is thought to result from the combination of 
immunologic mechanisms triggered by antibody binding to the cell surface and effects of 
radiation that are not limited to the bound cells but also affect neighboring „bystander“ cells. 
Currently two drugs are registered, ibritumomab and tositumomab, both directed against the 
CD20 antigen. In contrast to rituximab, these drugs result in prolonged myelosuppression. 
Currently, it seems that the best bet for radioimmunotherapy in NHL is to use it as a 
consolidation treatment after induction with immunochemotherapy or for conditioning prior 
to transplantation. Studies, designed to explore these possibilities, are underway.  
 
Smart drugs and cytotoxic agents 
  The proteasome inhibitor bortezomib and immunomodulators (or as some would claim, 
antiangiogenic agents) thalidomide and presumably lenalidomide are active in mantle-cell 
NHL (MCL) (5,6). They are being explored also in other types of lymphomas, most notably, 
diffuse large B-cell (DLBCL) and follicular lymphoma. HDAC inhibitors seem to be active in 
cutaneous T-cell NHL (CTCL) (7) and antiangiogenic drugs, such as bevacizumab, show 
some activity in aggressive NHL (8). Enzastaurin, a protein-kinase C (PKC) inhibitor, is 
being tested for remission maintenance in DLBCL.  
This abundance of „smart“ drugs has resulted in a shift away from testing new and 
improving combinations of classic cytotoxic agents that might not be completely appropriate. 
A rare example to the contrary is gemcitabine whose activity in hematological neoplasia has 
been long disregarded, but new studies confirm its activity in Hodgkin's lymphoma and NHL, 
especially CTCL of the peripheral T-cell type (PTCL) (9).  
 
Indolent B-NHLs 
 
 Indolent NHLs have a slow course and respond favorably to treatment but, unless 
localized, invariably relapse. Therefore, it is customary not to treat patients until they become 
symptomatic. Most patients with indolent NHL finally die of their disease but a significant 
proportion dies of unrelated diseases, 15% of them never needing lymphoma treatment. 
Rituximab is active as monotherapy, in combination with cytotoxic agents, in induction and 
remission maintenance, however only very few patients, if any, are cured with this approach. 
The biggest problem is not to achieve remission, but to prevent relapse. Therefore 
radioimmunotherapy consolidation after remission induction with immunochemotherapy, 
with or without autografting, seems a plausible option for achieving the holy grail of indolent 
NHL treatment, namely cure of disseminated disease. Trials are being planned to test this 
hypothesis. Whether immunomodulating agents or proteasome inhibitors will play a role in 
maintenance or, less probably, induction treatment remains to be seen. 
 
DLBCL 
 
 The addition of rituximab to CHOP resulted in 10-20% improved cure rates, still about 
40% of patients, most with high-risk features, die of their disease. Approximately half of the 
failures are due to refractoriness and half to relapses. Most relapses occur within a relatively 
short period of two years, indicating that, in contrast to indolent NHL, DLBCL cells are 
unable to survive long without proliferating. Currently it is everybody's guess whether the 
solution of the DLBCL problem lies with new cytotoxic agents, different combinations of 
standard cytotoxic agents (e.g. dose-adjusted EPOCH), radioimmunotherapy, PKC inhibitors, 
immunomodulators etc. but the author of this paper does not believe that it lies in shortening 
the interval between CHOP cycles from three to two weeks (10). Current data suggest that 
DLBCLs can be divided in at least two groups, those with gene expression profiles similar to 
germinal center B-cells (GC-type) and those similar to activated B-cells (ABC) (11). The 
latter have a worse prognosis. Future genetic studies might enable us to understand molecular 
changes leading to DLBCL development and design smart drugs that will interfere with these 
processes, in a way similar to the effect of imatinib in Ph+ CML. 
 
MCL 
 
 MCL has a bad prognosis, with less than 30% of patients surviving 5 years. This is due 
to its refractoriness to treatment (similar to DLBCL), propensity for relapsing (similar to 
indolent NHL) and the fact that it most frequently affects elderly patients unable to tolerate 
intensive chemotherapy. It seems that, at least in younger patients, an old cytotoxic agent, 
namely cytarabine, might improve the outcome, especially when combined with rituximab 
and autografting (12). Radioimmunotherapy might prove to be useful in patients with 
molecular, but probably not hematological, relapses. While the prospects for elderly are less 
bright, bortezomib, thalidomide and, presumably, lenalidomide containing combinations 
currently seem to be the best bet (4,5). 
 
PTCL 
 
 PTCLs also have a bad prognosis, with less than 30% of patients surviving 5 years. 
They do not express CD20 and have therefore largely remained untouched by improvements 
of the last decade. Intergroup randomized trials are being planned to test the value of 
alemtuzumab added to CHOP for induction treatment. However, for the purposes of 
prediction, one should not forget a few facts. First, the variability between PTCLs is even 
larger than between DLBCLs. Currently, we are not able to define real disease entities within 
this group and that, as well as their relative rarity in the developed world, hinders future 
improvements. Advances in biology might shed new light at PTCLs in a way that we are 
today unable to foresee. Second, the role of anthracyclines is less certain in PTCL than in B-
NHLs (13). If doxorubicin is not a very effective cytotoxic agent, new combinations, e.g. 
gemcitabine + cisplatin or high-dose methotrexate + l-asparaginase might be better than 
CHOP. Regarding new drugs, HDAC inhibitors are being explored in PTCLs (8). 
Angiommunoblastic lymphoma might be an attractive target for antiangiogenic drugs (but 
also for cyclosporine) (14,15). This is clearly a field where new approaches and better 
intergroup collaboration is needed. 
 
Burkitt's lymphoma (BL) 
 
 Let us end this paper on a brighter note. New data, coming from German researchers, 
suggests that BL should not be a problem in younger patients anymore, of course provided the 
diagnosis can be made and treatment started in time to prevent development of severe tumor-
lysis syndrome (16). The combination of rituximab and high-dose methotrexate based 
intensive chemotherapy results in cure rates up to 90%. Unfortunately, patients older than 50 
do not tolerate this type of treatment and their results are therefore inferior. Whether, like in 
osteosarcoma, different combinations of cytotoxic agents with equivalent activity and reduced 
toxicity can be found, remains to be seen. While relapsing or refractory BL is generally 
regarded as a lost cause, very preliminary data suggest that topotecan, a cytotoxic agent used 
for treatment of solid cancers, in combination with doxorubicin might show surprising activity 
(17).  
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